XtalPi topical hair loss candidate
IND-enabling per company
Since , the date of the source that reports this phase.
Summary
XtalPi topical hair loss candidate is a program from XtalPi. The source describes it as small molecule (topical). It is being developed for androgenetic alopecia. Per the company, it was at IND-enabling as of Oct 12, 2026. The AI role named in the source is molecule design. Mouse model: comparable hair growth to 5% minoxidil at 1/100th concentration. The latest dated source is from Oct 12, 2026.
Built only from the sources listed on this page.
Facts
- Company
- XtalPi
- Indication
- Androgenetic alopecia
- Therapeutic area
- Dermatology
- Modality
- Small molecule (topical)
- AI role
- Molecule design
- Phase in the source
- IND-enabling, as of Oct 12, 2026
- Phase source
- X only
- Board column
- Preclinical
- Trial record
- none (preclinical)
Key readouts in the source
Mouse model: comparable hair growth to 5% minoxidil at 1/100th concentration
AI evidence
AI source: Company
“The development of Remeanagen™ and AquaKine™ utilized XtalPi’s decade-long, multi-billion dollar investment in its ID4 AI Molecular Development Platform.”
Milestone timeline
-
Official X post: IND-enabling
Mouse model: comparable hair growth to 5% minoxidil at 1/100th concentration
Spot an error? Tell me and I'll fix it.